Search research articles
Contact Us
Filters
Showing results (261-270 of 293) with videos related to
Page
of 30
Sort By:
Anti-Cancer Drugs
|
February 9, 2018
Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung
Sanjeeve Balasubramaniam, Christophe E Redon, Cody J Peer, et al.
The International Journal of Biochemistry & Cell Biology
|
April 15, 2014
Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance
Hui Zhang, Rishil J Kathawala, Yi-Jun Wang, et al.
The Oncologist
|
March 18, 2026
Phase 2 Study of Azacitidine plus Pembrolizumab as Second-Line Treatment in Patients with Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
Rachael A Safyan, Ruth A White, Tamas A Gonda, et al.
The Oncologist
|
November 11, 2022
Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-World Data
Celine Yeh, Mengxi Zhou, Keith Sigel, et al.
British Journal of Haematology
|
October 31, 2009
Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma
Susan E Bates, Zhirong Zhan, Kenneth Steadman, et al.
Cancer
|
October 21, 2018
Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of Veterans Health Affairs data
Joshua M Bauml, Ravi Vinnakota, Yeun-Hee Anna Park, et al.
The Lancet. Oncology
|
December 17, 2016
Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis
Julia Wilkerson, Kald Abdallah, Charles Hugh-Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 16, 2002
Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms
Victor Sandor, Susan Bakke, Robert W Robey, et al.
Cancer Biology & Therapy
|
November 12, 2019
Botryllamide G is an ABCG2 inhibitor that improves lapatinib delivery in mouse brain
Jonathan D Strope, Cody J Peer, Tristan M Sissung, et al.
Oncotarget
|
July 2, 2014
Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2
De-Shen Wang, Atish Patel, Suneet Shukla, et al.
Page
of 30
Search research articles
Search
Showing results (261-270 of 293) with videos related to
Sort By:
Page
of 30
Anti-Cancer Drugs
|
February 9, 2018
Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung
Sanjeeve Balasubramaniam, Christophe E Redon, Cody J Peer, et al.
The International Journal of Biochemistry & Cell Biology
|
April 15, 2014
Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance
Hui Zhang, Rishil J Kathawala, Yi-Jun Wang, et al.
The Oncologist
|
March 18, 2026
Phase 2 Study of Azacitidine plus Pembrolizumab as Second-Line Treatment in Patients with Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
Rachael A Safyan, Ruth A White, Tamas A Gonda, et al.
The Oncologist
|
November 11, 2022
Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-World Data
Celine Yeh, Mengxi Zhou, Keith Sigel, et al.
British Journal of Haematology
|
October 31, 2009
Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma
Susan E Bates, Zhirong Zhan, Kenneth Steadman, et al.
Cancer
|
October 21, 2018
Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of Veterans Health Affairs data
Joshua M Bauml, Ravi Vinnakota, Yeun-Hee Anna Park, et al.
The Lancet. Oncology
|
December 17, 2016
Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis
Julia Wilkerson, Kald Abdallah, Charles Hugh-Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 16, 2002
Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms
Victor Sandor, Susan Bakke, Robert W Robey, et al.
Cancer Biology & Therapy
|
November 12, 2019
Botryllamide G is an ABCG2 inhibitor that improves lapatinib delivery in mouse brain
Jonathan D Strope, Cody J Peer, Tristan M Sissung, et al.
Oncotarget
|
July 2, 2014
Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2
De-Shen Wang, Atish Patel, Suneet Shukla, et al.
Page
of 30